San Antonio, Texas
Cancer biologic therapy trials in San Antonio, TX
35 cancer biologic therapy studies are recruiting participants at sites in San Antonio as of November 18, 2026, according to ClinicalTrials.gov. Cancer Biologic Trials can help you understand your options and connect with a study team.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
San Antonio at a glance
- 35 studies are recruiting at a site in San Antonio.
- By phase: Phase 1 (11), Phase 1/2 (3), Phase 2 (9), Phase 3 (12).
- By sponsor: industry (27), government (6), university, hospital or other (2).
- By research area: Breast Cancer (14), Lymphoma (14), Lung Cancer (3), Pancreatic Cancer (2), Melanoma (1), Prostate Cancer (1).
- Most recent update to one of these records: November 18, 2026.
Breast cancer studies recruiting in San Antonio
Basic details from each study's public record (the 30 most recently updated of 35). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Mays Cancer Center ( Site 0122)
- Registry record
- NCT06393374 · updated
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Texas Oncology - San Antonio ( Site 8001)
- Registry record
- NCT06841354 · updated
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Texas Oncology - San Antonio ( Site 8004)
- Registry record
- NCT06966700 · updated
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- University of Texas Health Science Center at San Antonio
- Registry record
- NCT06058377 · updated
Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer
- Phase 1
- Ages 18 and older
- Female participants
- Sponsor
- Immunomic Therapeutics, Inc.
- Study site
- START San Antonio
- Registry record
- NCT07652242 · updated
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Mays Cancer Center ( Site 0049)
- Registry record
- NCT07060807 · updated
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Nammi Therapeutics Inc
- Study site
- START San Antonio
- Registry record
- NCT06582017 · updated
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Texas Oncology - San Antonio ( Site 8002)
- Registry record
- NCT06312176 · updated
A Study of PHST001 in Advanced Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Pheast Therapeutics
- Study sites
- START Center for Cancer Research - San Antonio · University of Texas (UT) Health
- Registry record
- NCT06840886 · updated
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- BriaCell Therapeutics Corporation
- Study sites
- Texas Oncology - San Antonio Northeast · Texas Oncology - San Antonio Stone Oak · Texas Oncology-San Antonio Cancer Care
- Registry record
- NCT06072612 · updated
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
- Phase 3
- Ages 18 to 100
- All sexes
- Sponsor
- Greenwich LifeSciences, Inc.
- Study sites
- Texas Oncology - San Antonio Medical Center · The University of Texas Health Sciences Center at San Antonio - Mays Cancer Center
- Registry record
- NCT05232916 · updated
IDOV-Immune for Advanced Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- ViroMissile, Inc.
- Study site
- South Texas Accelerated Research Therapeutics
- Registry record
- NCT06910657 · updated
Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in San Antonio, TX on ClinicalTrials.gov.
Lung cancer studies recruiting in San Antonio
M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- EMD Serono Research & Development Institute, Inc.
- Study site
- NEXT Oncology
- Registry record
- NCT07166601 · updated
DBC-664 in Adult Patients With Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Duboce Biopharmaceuticals, Inc.
- Study site
- START San Antonio
- Registry record
- NCT07705035 · updated
Autologous Adipose-Derived Mesenchymal Stem Cells for Chronic Traumatic Brain Injury
- Phase 2
- Ages 18 to 55
- All sexes
- Sponsor
- Hope Biosciences LLC
- Study site
- The University of Texas Health Science at San Antonio
- Registry record
- NCT05951777 · updated
Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in San Antonio, TX on ClinicalTrials.gov.
Prostate cancer studies recruiting in San Antonio
JUR-003 in Adult Patients With Metastatic Prostate Cancer
- Phase 1
- Ages 18 and older
- Male participants
- Sponsor
- Juri Biosciences, Inc.
- Study site
- START San Antonio
- Registry record
- NCT07824349 · updated
Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in San Antonio, TX on ClinicalTrials.gov.
Melanoma studies recruiting in San Antonio
A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- ModernaTX, Inc.
- Study site
- START San Antonio
- Registry record
- NCT06880549 · updated
Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in San Antonio, TX on ClinicalTrials.gov.
Lymphoma studies recruiting in San Antonio
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Phase 2
- Up to 365 days
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Children's Hospital of San Antonio · Methodist Children's Hospital of South Texas
- Registry record
- NCT06317662 · updated
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- University of Texas Health Science Center at San Antonio
- Registry record
- NCT06337318 · updated
A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
- Phase 1
- Ages 0 to 18
- All sexes
- Sponsor
- Autolus Limited
- Study site
- Methodist Children's Hospital
- Registry record
- NCT06173518 · updated
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Texas Oncology - San Antonio ( Site 8009)
- Registry record
- NCT06890884 · updated
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Phase 2
- Ages 1 to 30
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Children's Hospital of San Antonio · Methodist Children's Hospital of South Texas · University of Texas Health Science Center at San Antonio
- Registry record
- NCT04546399 · updated
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
- Phase 3
- Ages 5 to 60
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Children's Hospital of San Antonio · Methodist Children's Hospital of South Texas · University of Texas Health Science Center at San Antonio
- Registry record
- NCT05675410 · updated
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Lyell Immunopharma, Inc.
- Study site
- Texas Transplant Institute
- Registry record
- NCT07188558 · updated
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Allogene Therapeutics
- Study site
- Texas Transplant Institute
- Registry record
- NCT06500273 · updated
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- SWOG Cancer Research Network
- Study site
- University of Texas Health Science Center at San Antonio
- Registry record
- NCT05890352 · updated
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Phase 2
- From 366 days, up to 46 years
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Children's Hospital of San Antonio · Methodist Children's Hospital of South Texas · University of Texas Health Science Center at San Antonio
- Registry record
- NCT06124157 · updated
A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)
- Phase 2
- From 6 months
- All sexes
- Sponsor
- Allotera Therapeutics
- Study site
- Sarah Cannon Transplant and Cellular Therapy Methodist Hospital
- Registry record
- NCT06514794 · updated
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Phase 3
- From 365 days, up to 25 years
- All sexes
- Sponsor
- Children's Oncology Group
- Study sites
- Children's Hospital of San Antonio · Methodist Children's Hospital of South Texas · University of Texas Health Science Center at San Antonio
- Registry record
- NCT03959085 · updated
Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in San Antonio, TX on ClinicalTrials.gov.
Pancreatic cancer studies recruiting in San Antonio
A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- GlaxoSmithKline
- Study site
- GSK Investigational Site
- Registry record
- NCT06885034 · updated
Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in San Antonio, TX on ClinicalTrials.gov.
Ask about studies near San Antonio
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
More locations in Texas
All Texas locations
140 studies recruiting across 53 cities.
Houston
101 studies recruiting.
Dallas
46 studies recruiting.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a biologic, such as a vaccine, an antibody, or a cell or gene therapy, as each study is coded in the registry.
Cancer Biologic Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections